Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy
Jing Xing,*,1,2 Xiquan Zhang,*,3 Zhe Wang,4 Huanqing Zhang,3 Peng Chen,1,2 Gaoxin Zhou,5 Chunlong Sun,6 Ning Gu,1,2 Min Ji1,21School of Biological Science and Medical Engineering, Southeast University, Nanjing 210096, People’s Republic of China; 2School of Biolog...
Guardado en:
Autores principales: | Xing J, Zhang X, Wang Z, Zhang H, Chen P, Zhou G, Sun C, Gu N, Ji M |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cf22458adb33452bb085be34abb12b48 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Novel SN38 derivative-based liposome as anticancer prodrug: an in vitro and in vivo study
por: Wu C, et al.
Publicado: (2018) -
Liposomal codelivery of an SN38 prodrug and a survivin siRNA for tumor therapy
por: Bi Y, et al.
Publicado: (2018) -
Liposomal formulation of a methotrexate lipophilic prodrug: assessment in tumor cells and mouse T-cell leukemic lymphoma
por: Alekseeva AA, et al.
Publicado: (2017) -
SN38-loaded <100 nm targeted liposomes for improving poor solubility and minimizing burst release and toxicity: in vitro and in vivo study
por: Fang YP, et al.
Publicado: (2018) -
A novel microfluidic liposomal formulation for the delivery of the SN-38 camptothecin: characterization and in vitro assessment of its cytotoxic effect on two tumor cell lines
por: Casadó A, et al.
Publicado: (2018)